ResMed Inc. (NYSE:RMD) insider Robert Andrew Douglas sold 4,200 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $111.35, for a total transaction of $467,670.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Robert Andrew Douglas also recently made the following trade(s):
- On Monday, April 15th, Robert Andrew Douglas sold 4,285 shares of ResMed stock. The stock was sold at an average price of $102.29, for a total transaction of $438,312.65.
- On Friday, March 15th, Robert Andrew Douglas sold 4,298 shares of ResMed stock. The stock was sold at an average price of $100.90, for a total transaction of $433,668.20.
- On Friday, February 15th, Robert Andrew Douglas sold 4,313 shares of ResMed stock. The stock was sold at an average price of $99.95, for a total transaction of $431,084.35.
RMD traded down $0.71 on Friday, reaching $112.72. The company had a trading volume of 42,529 shares, compared to its average volume of 654,423. The firm has a market capitalization of $16.18 billion, a PE ratio of 32.01, a P/E/G ratio of 2.93 and a beta of 0.56. The company has a quick ratio of 1.69, a current ratio of 2.38 and a debt-to-equity ratio of 0.65. ResMed Inc. has a one year low of $90.64 and a one year high of $118.50.
ResMed (NYSE:RMD) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $0.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.84 by $0.05. The firm had revenue of $662.23 million during the quarter, compared to analyst estimates of $657.82 million. ResMed had a net margin of 17.65% and a return on equity of 26.46%. ResMed’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.92 EPS. On average, equities analysts expect that ResMed Inc. will post 3.63 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 13th. Investors of record on Thursday, May 9th will be given a $0.37 dividend. The ex-dividend date is Wednesday, May 8th. This represents a $1.48 dividend on an annualized basis and a yield of 1.31%. ResMed’s dividend payout ratio is presently 41.93%.
Several equities analysts have recently commented on RMD shares. JPMorgan Chase & Co. lowered shares of ResMed from a “neutral” rating to an “underweight” rating and set a $99.60 price target for the company. in a research report on Friday, January 25th. Deutsche Bank lowered shares of ResMed from a “buy” rating to a “hold” rating in a research report on Wednesday, January 23rd. BMO Capital Markets decreased their target price on shares of ResMed to $120.00 and set a “positive” rating for the company in a research report on Monday, January 28th. ValuEngine lowered shares of ResMed from a “buy” rating to a “hold” rating in a research report on Thursday, April 4th. Finally, Goldman Sachs Group lowered shares of ResMed from a “buy” rating to a “neutral” rating in a research report on Friday, January 25th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $112.50.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Farmers & Merchants Investments Inc. lifted its holdings in ResMed by 49.0% in the 1st quarter. Farmers & Merchants Investments Inc. now owns 295 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 97 shares during the last quarter. Executive Wealth Management LLC acquired a new position in shares of ResMed in the 4th quarter valued at about $35,000. Parallel Advisors LLC increased its holdings in shares of ResMed by 143.0% in the 4th quarter. Parallel Advisors LLC now owns 328 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 193 shares during the period. Financial Gravity Companies Inc. acquired a new position in shares of ResMed in the 4th quarter valued at about $34,000. Finally, Pinnacle Bank acquired a new position in shares of ResMed in the 4th quarter valued at about $42,000. Hedge funds and other institutional investors own 67.91% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Robert Andrew Douglas Sells 4,200 Shares of ResMed Inc. (RMD) Stock” was originally reported by Modern Readers and is the sole property of of Modern Readers. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.modernreaders.com/news/2019/05/17/robert-andrew-douglas-sells-4200-shares-of-resmed-inc-rmd-stock.html.
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Featured Story: What is an investor looking for in an SEC filing?
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.